Successful Use of Cyclosporin A for Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Three Children
Pediatric Dermatology2017Vol. 34(5), pp. 540–546
Citations Over TimeTop 10% of 2017 papers
Jessica St. John, Vladimir Ratushny, Kristina J. Liu, Daniel Q. Bach, Omar Badri, Lia E. Gracey, Allen W. Ho, Adam B. Raff, Daniel Y. Sugai, Peter C. Schalock, Daniela Kroshinsky
Abstract
We describe three pediatric patients treated successfully with CsA and provide evidence for the use of cyclosporine in children with SJS/TEN. These results further support previous observations that CsA use for SJS/TEN produces consistently favorable outcomes. The results in this case series are limited by their observational nature. Additional trials are needed to evaluate the safety and efficacy of CsA use in children.
Related Papers
- → Toxic epidermal necrolysis: a paradigm of critical illness(2017)34 cited
- → Stevens-Johnson syndrome and toxic epidermal necrolysis(2017)19 cited
- → Pattern and impact of drug-induced liver injury in South African patients with Stevens-Johnson syndrome/toxic epidermal necrolysis and a high burden of HIV(2021)4 cited
- → A Case Study of Toxic Epidermal Necrolysis(2019)1 cited
- → Predicting sepsis in Stevens-Johnson syndrome–toxic epidermal necrolysis: Should dermatologists be pro-procalcitonin?(2019)